Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
56.97
-0.15 (-0.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,883,250
Open
57.25
Bid (Size)
56.08 (1)
Ask (Size)
57.69 (30)
Prev. Close
57.12
Today's Range
56.77 - 57.09
52wk Range
50.27 - 76.04
Shares Outstanding
222,430,635
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
March 26, 2024
INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals.
Via
Chartmill
NASDAQ:INCY, a growth stock which is not overvalued.
March 15, 2024
Despite its growth, NASDAQ:INCY remains within the realm of affordability.
Via
Chartmill
Performance
YTD
-12.96%
-12.96%
1 Month
-6.61%
-6.61%
3 Month
-9.18%
-9.18%
6 Month
-2.80%
-2.80%
1 Year
-19.92%
-19.92%
More News
Read More
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
March 12, 2024
Via
Benzinga
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
March 11, 2024
Via
InvestorPlace
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
March 10, 2024
From
Incyte Corporation
Via
Business Wire
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
March 04, 2024
Via
Chartmill
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
February 14, 2024
Via
Benzinga
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
March 10, 2024
From
Incyte
Via
Business Wire
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
March 07, 2024
Via
InvestorPlace
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 04, 2024
From
Incyte
Via
Business Wire
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
February 29, 2024
From
Incyte
Via
Business Wire
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
February 27, 2024
From
Incyte
Via
Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
February 26, 2024
Via
InvestorPlace
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
February 22, 2024
Via
Chartmill
Exit Now! 3 Biotech Stocks to Sell in February 2024
February 21, 2024
Via
InvestorPlace
Incyte to Present at Upcoming Investor Conference
February 15, 2024
From
Incyte
Via
Business Wire
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
February 13, 2024
From
Incyte
Via
Business Wire
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
February 12, 2024
Via
Chartmill
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
Via
FinancialNewsMedia
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
February 06, 2024
Via
Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
Via
Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
February 05, 2024
Via
Investor's Business Daily
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
February 05, 2024
From
Incyte
Via
Business Wire
Why Is MorphoSys (MOR) Stock Up 50% Today?
February 05, 2024
Via
InvestorPlace
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
February 05, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.